In the genomic analysis of LUAD, the levels of CTNNB1 were higher in patients with metastatic stages 3 and 4 (46%, 7 tumors/15 total) than in those with tumor stage 1 (27%; 8 tumors/29 total) (Figure 1D), indicating that β-catenin and PLK1 are markedly expressed in metastatic NSCLC, especially in LUAD. The gene discussed is CTNNB1; the disease is neoplasm.